Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 755.75

+2.5%

Nov 21 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2015)	1/20/2017 2:06:07 PM
From: Biotech Jim	of 3559

Asclepius was was a hero and god of medicine in ancient Greek religion and mythology. AsclepiX Therapeutics: This company from an academic viewpoint seems to fit the above, at least with basic research and innovation in ocular sciences. Nice patent publication estate, though I have not looked at too many yet. But is the extent of technology sufficient to transform treatment approaches? My bottom line to your question: Yes Parking the titles of the patents here. They make it easy to check out their innovations. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors Poly(ß-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo. Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth Gene delivery nanoparticles specific for human microvasculature and macrovasculature Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next